title: Intravenous ilaprazole is more potent than oral ilaprazole against gastric lesions in rats.
abstract: OBJECTIVE
  Ilaprazole is a novel proton pump inhibitor that has been marketed as an oral therapy for acid-related diseases in China and Korea. This study aimed to compare the gastroprotective effects of intravenous and enteral ilaprazole in rat models.
  
  
  METHODS
  The rats were divided into 7-8 groups receiving vehicle, esomeprazole, and different doses of intravenous and enteral ilaprazole. The rats were then exposed to indomethacin (30 mg/kg, i.g.), or water-immersion stress and gastric lesions were examined. The effects of different treatments on histamine (10 μmol/kg/h)-induced acid secretion were also observed.
  
  
  RESULTS
  Intravenous ilaprazole exhibited high antiulcer activity in a dose-dependent manner. Ilaprazole at a dose of 3 mg/kg decreased ulcer number and index to the same extent as 20 mg/kg esomeprazole. Moreover, the potency of intravenous ilaprazole is superior to that of intragastric ilaprazole. In anesthetized rats, the inhibitory effect of intravenous ilaprazole on histamine-induced acid secretion is faster and longer-lasting than that of intraduodenal ilaprazole.
  
  
  CONCLUSIONS
  Intravenous ilaprazole is more potent than oral ilaprazole against indomethacin- or stress-induced gastric lesions, with faster and longer inhibition of acid secretion.
authors.affiliation: Department of New Drug Evaluation, Beijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing, 100850, China, yg1st@163.com.
authors.forename: Gang
authors.initials: G
authors.lastname: Yu
authors.forename: Xin-Qiang
authors.initials: XQ
authors.lastname: Lu
authors.forename: Rui-Bin
authors.initials: RB
authors.lastname: Su
authors.forename: Ze-Hui
authors.initials: ZH
authors.lastname: Gong
authors.forename: He-Zhi
authors.initials: HZ
authors.lastname: Xie
authors.forename: Hai-Tang
authors.initials: HT
authors.lastname: Hu
authors.forename: Xue-Mei
authors.initials: XM
authors.lastname: Hou
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage* / Q000627:therapeutic use*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000633:toxicity; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000378:metabolism; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D006632:Histamine / Q000494:pharmacology; D007213:Indomethacin / Q000633:toxicity; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013270:Stomach / Q000187:drug effects / Q000473:pathology; D013276:Stomach Ulcer / Q000188:drug therapy*; D013312:Stress, Physiological
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000894:Anti-Inflammatory Agents, Non-Steroidal; D005765:Gastrointestinal Agents; C119615:ilaprazole; D006632:Histamine; D007213:Indomethacin